Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma

Clinical Cancer Research

Volumn 2, Issue 1, 1996, Pages 21-28

  Ockert, Detlef ^a,d   Schirrmacher, Volker ^c   Beck, Nicole ^a   Stoelben, Erich ^d   Ahlert, Thorsten ^b   Flechtenmacher, Johannes ^a   Hagmüller, Egbert ^a   Buchcik, René ^d   Nagel, Michael ^a,d   Saeger, Hans Detlev ^a,d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CANCER VACCINE;

ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; BIRD DISEASE; CANCER CELL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ERYTHEMA; FEMALE; HUMAN; IMMUNOTHERAPY; INJECTION PAIN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AGED; CANCER VACCINES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOTHERAPY, ACTIVE; MALE; MIDDLE AGED; NEWCASTLE DISEASE VIRUS; SURVIVAL RATE;

EID: 8944263472     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. August, D. A., Ottow, R T., and Sugarbaker, P. H Clinical perspectives on human colorectal cancer metastases. Cancer Metastasis Rev , 3: 303-324, 1984.
2. Moertel, C. G., Fleming, T. R., MacDonald, J. S., Haller, D. G., Laurie, J. A., Goodman, P. J., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., Veeder, M. H., and Mailliard, J. A. Levamisole and fluoruracil for adjuvant therapy of resected colon carcinoma. N. Engl. J Med , 322: 352-358, 1990.
3. Coley, W. B. The treatment of malignant tumors by repeated inoculations of Erysipelas: with a report of ten original cases. Am. J. Med. Sci., 105: 487, 1993.
4. von Leyden, E., and Blumenthal, F. Attempts to immunize humans by inoculation of their own cancer, Dtsch. Med. Wochenschr., 28: 637-638, 1902.
5. Oettgen, H. F., and Old, L. J. The history of cancer immunotherapy. In: V. T. de Vita, S. Hellman, and S. A. Rosenberg (eds.), Biologic Therapy of Cancer, pp. 87-122. Philadelphia: J. B. Lippincott, 1991.
6. Hoover, H. C., Surdyke, M G., Dangel, R. B., Peters, L. C., and Hanna, M. G. Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer (Phila.). 55: 1236-1243, 1985.
7. Schlag, P., Manasterski, M., Gerneth, T., Hohenberger, P., Dueck, M., Herfarth, C., Liebrich, W., and Schirrmacher, V. Active specific immunotherapy with NDV modified autologous tumor cells following liver metastases resection in colorectal cancer: first evaluation of clinical response of a phase II trial. Cancer Immunol. Immunother. 35: 325-330, 1992.
8. Hoover, H. C., Brandhorst, J. S., Peters, L. C., Surdyke, M. G., Takeshita, Y., Madanaga, J , Muenz, L. R., and Hanna, M. G. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up. A phase III prospectively randomized trial. J. Clin. Oncol., 11: 390-399, 1993.
9. Riethmüller, G., Schneider-Gädicke, E., Schlimok, G., Schmiegel, W., Raab, R., Höffken, K., Gruber, R., Pichlmayr, H., Hirche, H., Pichlmayr, R., Buggisch, P., and Witte, J. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes'C colorectal carcinoma. Lancet, 343: 1177-1183, 1994.
10. Hanna, M. G., Brandhorst, J. S., and Peters, L. C. Active specific immunotherapy of residual micrometastasis: an evaluation of sources, doses and ratios of BCG with tumor cells. Cancer Immunol. Immunother., 7: 165-173, 1979.
11. Heicappell, R., Schirrmacher, V., Von Hoegen, P., Ahlert, T., and Appelhans, P. Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells: I. Parameters for optimal therapeutic effects. Int. J. Cancer, 37: 569-577, 1986.
12. Schirrmacher, V., Ahlert, T., Heicappell, R., Appelhans, B., and von Hoegen, P. Successful application of non-oncogenic viruses for antimetastatic cancer immunotherapy. Cancer Rev., 5: 19-49, 1986.
13. Schirrmacher, V., and Heicappell, R. Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells: II. Establishment of specific anti-tumor immunity. Clin. Exp. Metastasis, 5: 147-156, 1987.
14. Schirrmacher, V., von Hoegen, P., Schlag, P., Liebrich, W., Lehner, B., Schumacher, K., Ahlert, T., and Bastert, G. Active specific immunotherapy with autologous tumor cell vaccines modified by Newcastle disease virus: experimental and clinical studies. In: V. Schirrmacher and R. Schwartz-Albiez (eds.), Cancer Metastasis, pp. 157-170. Berlin: Springer-Verlag, 1989.
15. Schirrmacher, V. Immunity and metastasis: in situ activation of protective T cells by virus modified cancer vaccines. Cancer Surv., 13: 129-154, 1992.
16. Schirrmacher, V , and von Hoegen, P. Importance of tumor cell membrane integrity and viability for CTL activation by cancer vaccines. Vaccine Res., 50: 5962-5968, 1993.
17. Schirrmacher, V., Griesbach, A., and Zangemeisier-Wittke, U. γ-Irradiated viable tumor cells as whole cell vaccines can stimulate in situ syngeneic anti-tumor CTL and DTH reactivity while tumor cell lysates elicit only DTH reactivity. Vaccine Res., 3: 31-48, 1994.
18. Von Hoegen, P., Weber, E., and Schirrmacher, V. Modification of tumor cells by a low dose of Newcastle disease virus: augmentation of the tumor-specific T cell response m the absence of an anti-viral response. Eur. J. Immunol., 18: 1159-1166, 1988.
19. Von Hoegen, P., Zawatzky, R., and Schirrmacher, V. Modification of tumor cells by a low dose of Newcastle disease virus: III. Potentiation of tumor specific cytolytic T cell activity via induction of interferon, alpha, beta. Cell. Immunol., 126: 80-90, 1990.
20. Ertel, C., Millar, N. S , Emmerson, P. T., Schirrmacher, V., and von Hoegen, P. Viral hemagglutinin augments peptide specific cytotoxic T-cell responses. Eur J. Immunol., 23: 2592-2596, 1993.
21. Boon, T. Genetic Analysis of tumor rejection antigens. Adv. Cancer Res., 58: 177-210, 1992.
22. Wang, P., Vegh, Z., Vanky, F., and Klein, E. HLA-B5 restricted auto-tumor-specific cytotoxic T cells generated in mixed lymphocyte-tumor-cell culture. Int J. Cancer, 52: 517-522, 1992.
23. Van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., de Plaen, E., van den Eynde, B., Knutz, A., and Boon, T A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (Washington DC), 254: 1643-1647, 1991.
24. Brichard, V., Van Pel, A., Wolfel, T., et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med., 178: 489, 1993.
25. Yasumura, S., Hirabayashi, H., Schwartz, D. R., Toso, J. F., Johnson, J. T., Herberman, R. B., and Whiteside, T. L. Human cytotoxic T cell lines with restricted specificity for squamous cell carcinoma of the head and neck. Cancer Res., 53: 1461-1468, 1993.
26. Schendel, D. J. Abstract NZ 218, Keystone Symposium on Cellular Immunity and Immunotherapy of Cancer, Taos, New Mexico, March 1993.
27. Jerome, K. R., Domenech, N., and Finn, O. J. Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin DNA. J. Immunol. 151: 1654-1662, 1993.
28. Magarian-Blander, J., Domenech, N., and Finn, O. J. Specific and effective T cell recognition of cells transfected with a truncated human mucin cDNA. Ann. NY Acad. Sci., 690: 231-244, 1993.
29. Peoples, G. E., Goedegebune, P. S., Smith, R., Linehan, D. C., Yoshino, I., and Eberlein, T. J. Breast and ovarian cancer specific cytotoxic T-lymphocytes recognize the same HER2/neu-derived peptide. Proc. Natl. Acad. Sci. USA, 92: 432-436, 1995.
30. Patel, B. T., Lutz, M. B., Schlag, P., and Schirrmacher, V. An analysis of autologous T-cell anti-tumor responses in colon carcinoma patients following active specific immunization (ASI). Int. J. Cancer, 51: 878-885, 1992.
31. Zöller, M., Matzku, S., and Schulz, U. Colorectal cancer diagnosis by a direct leukocyte migration test using a panel of tumor extracts. Cancer Immunol. Immunother., 2 257-265, 1977
32. Jung, S., and Schluesener, H. J. Human T lymphocytes recognize a peptide of single point mutated oncogenic ras proteins. J Exp. Med., 173: 273-276, 1991.
33. Gedde-Dahl, T., III, Spurkland, A., Eriksen, J. A., Thorsby, E., and Gaudernack, G. Memory T cells of a patient with follicular thyroid carcinoma recognizing peptides derived from mutated p21 ras. Int. Immunol., 4: 1331-1337, 1992.
34. Gedde-Dahl, T., III, Eriksen, J. A., Thorsby, E., and Gaudernack, G. T cell responses against products of oncogenes. Generation and characterization of human T cell clones specific for p21 ras derived synthetic peptides. Hum. Immunol., 33: 266-273, 1992.
35. Gedde-Dahl, T., III, Nilsen, E., Thorsby, E., and Gaudernack, G. Growth inhibition of a colonic adenocarcinoma cell line (HT 29) by T cells specific for mutant p21 ras. Cancer Immunol. Immunother., 38: 127-134, 1994.
36. Burkart, C. Das Tumor suppressor protein p53. Dt. Aerzteblatt, 91: A-898-904, 1994.
37. Houbiers, J. G. A., Nijman, H. W., van der Burg, S. H, Drijfhout, J. W., Kenemans, P., van de Velde, C. J. H , Brand, A., Momburg, F., Kast, W. M., and Melief, C. J. M. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol., 23: 2072-2077, 1993.
38. Bloemena, E., Gall, H., Ransom, J. H., Pomato, N., Murray, J. H., Bos, E., Scheper, R. J., Meijer, C. J. L. M., Hann, M. G., and Vermorken, J. B. Delayed-type hypersensitivity reactions to tumor-associated antigens in colon carcinoma patients immunized with an autologous tumor cell/Bacillus Calmette-Gu'erin vaccine. Cancer Res., 53: 456-459, 1993.
39. Ransom, J. H., Pelle, B. A., Hubers, H., Keynton, L. M., Hanna, M. G., and Pomato, N. Identification of colon-tumor associated antigens by T-cell lines derived from tumor-infiltrating lymphocytes and peripheral blood lymphocytes from patients immunized with an autologous tumor-cell/Bacillus Calmette-Guerin vaccine. Int. J. Cancer, 54: 734-740, 1993.
40. Cassel, W. A., and Garrett, R. E. Newcastle disease virus as an antineoplastic agent. Cancer (Phila.), 18: 863-869, 1965.
41. Csatary, L., Eckhard, S., Bukosza, I., Czegledi, F., Fenyvesi, C., Gergely P., Bodey, B., and Csatary, C. M. Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect. Prevent., 17: 619-627, 1993.
42. Bohle, W , Schlag, P., Liebrich, W., Hohenberger, P., Manasterski, M., Möller, P., and Schirrmacher, V. Postoperative active specific immunization in colorectal cancer patients with virus-modified autologous tumor-cell vaccine. Cancer (Phila.), 66: 1517-1523, 1990.
43. Liebrich, W., Lehner, B., Möller, P., Schirrmacher, V., and Schlag, P. Preparation and characterization of a new type of tumor cell vaccine: surface modified human colon cells using Newcastle disease virus (NDV). Clin. Exp. Metastasis (Suppl), 6: 80-81, 1988.
44. Krook, J. E., Moertel, C. G., Gunderson, L. L., Wieand, H. S., Collins, R. T., Beart, R. W., Kubista, T. P., Poon, M. A., Meyers, W. C., Mailliard, J. A., Twito, D. I., Morton, R. F., Veeder, M. H., Witzig, T. E., Ca, S., and Vidyarthi, S. C. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl. J. Med., 324: 709-715, 1991.